Amgenâ€™s Q1 earnings call revealed a complex operating landscape, with mixed signals impacting stock performance in the short term. The delayed business review, uncertain ESA labels, and evolving Denosumab data are significant concerns. However, robust R&D expenditures, an encouraging product pipeline, and strategic collaborations for market expansion